Biotech startup 23Strands is planning to take genomics into mainstream healthcare by way of its cutting-edge analysis and improvements in bioinformatics, scientific literature evaluation, and scientific insights primarily based on entire genome sequencing (WGS).

A human physique comprises round 3 billion pairs of genes. However the perform of each gene continues to be not recognized. Genome sequencing hyperlinks genes to their perform and 23Strands is hoping to unlock these particulars to revolutionise healthcare business and the way medical remedy is delivered. 

The Sydney startup makes use of synthetic intelligence (AI) to entire genome sequencing to ship personalised medical remedies, and has established collaborations with a variety of outstanding medical analysis companions.

The AI-driven applied sciences have the potential to revolutionise illness analysis, drug discovery, therapeutic interventions, scientific choice assist methods, and automatic scientific reporting. 

CEO Mark Grosser stated 23Strands is making important inroads utilizing AI and genome sequencing in scientific, analysis and industrial settings.

“We’re proud to broaden our college collaboration with UNSW since being one in all 10 firms to undergo the UNSW Health10X accelerator in 2020,” he stated

“This program will complement the superb work we’re doing with others, resembling Professor Jie Lu and her crew on the Australian Synthetic Intelligence Institute and UTS, and we’re eager on making use of AI to necessary well being challenges, resembling uncommon childhood illnesses.”

The initiatives 23Strands is engaged on embrace the Baker Coronary heart and Diabetes Institute to develop a brand new technique for early coronary heart illness identification and remedy to forestall coronary heart assaults. They acquired a $1 million grant to measure genetic and way of life markers, and the startup may also ship a digital well being knowledge platform combining a affected person’s well being knowledge from a number of sources. 

Indigenous Australians are additionally a spotlight in a nationwide collaboration between business, researchers, Indigenous neighborhood well being organisations, and genetic specialists, to develop genomic analysis and assets to enhance the lives of Aboriginal and Torres Strait Islander peoples, backed by a $5 million Synergy grant from the Nationwide Well being and Medical Analysis Council. 

In the meantime, 23Strands is a key business accomplice within the mission led by CAD Frontiers‘ Professor Gemma Figtree, which goals to forestall coronary heart assaults by discovering and implementing new blood biomarkers that establish silent coronary artery illness (CAD), in addition to new medication that focus on a person’s CAD susceptibility and cease illness development. 

And nationwide science physique CSIRO selected 23Strands as an business accomplice to develop AI-driven medical applied sciences to assist sufferers, clinicians and the healthcare system.